^
Association details:
Biomarker:JAK2 R683G
Cancer:Acute Lymphocytic Leukemia
Drug:sirolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

Excerpt:
Rapamycin significantly prolonged survival compared with vehicle of both xenograft IV (Figure 5A, median survival 63 days vs 23 days, P < .01) and xenograft V (Figure 5B, median survival 91 days vs 58 days, P < .01).
DOI:
10.1182%2Fblood-2012-03-415448